Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283306 | 0.83 | HCAR2 (0.34) | ALDH1A1HCAR2KDM4EMAPTTGFBR1 | |
| SCHEMBL18283305 | 0.83 | HCAR2 (0.34) | ALDH1A1HCAR2KDM4EMAPTTGFBR1 | |
| SCHEMBL13285305 | 0.82 | ALDH1A1 (0.35) | ALDH1A1KEAP1NFE2L2HCAR2SMN1; SMN2 | |
| SCHEMBL41569 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KEAP1NFE2L2HCAR2SMN1; SMN2 | |
| SCHEMBL28826497 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KEAP1NFE2L2HCAR2SMN1; SMN2 | |
| SCHEMBL10687985 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KEAP1NFE2L2HCAR2SMN1; SMN2 | |
| SCHEMBL6109387 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TGFBR1TET2EGLN1 | |
| SCHEMBL23551429 | 0.78 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL8641917 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL9255843 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173395-B2 | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | NQO1, NFE2, NDUFS1 | ALDH1A1 728/4885KEAP1 10/4885NFE2L2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.